CIK 0001023024 · Large accelerated filer
ANI PHARMACEUTICALS INC
Sign in to watch- Ticker
- ANIP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 582301143
- Phone
- 6097591810
- Business address
- 104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, NJ, 08540
- Former names
- BIOSANTE PHARMACEUTICALS INC, BEN ABRAHAM TECHNOLOGIES INC
- 4 Shares withheld for taxes SVP, GENERICS gave up 4,267 shares (to pay taxes)
- 4 Shares withheld for taxes PRESIDENT & CEO gave up 30,659 shares (to pay taxes)
- 4 Shares withheld for taxes HEAD OF RARE DISEASE gave up 4,546 shares (to pay taxes)
- 4 Shares withheld for taxes SVP, HEAD - ESTABLISHED BRANDS gave up 1,762 shares (to pay taxes)
- 4 Shares withheld for taxes HEAD OF R&D, COO-NOVITIUM OPS gave up 2,898 shares (to pay taxes)
- 4 Planned sale SR. VP, GENERAL COUNSEL & SEC. sold 500 shares at $84.33 ($42,165)
- 8-K Event Results of operations · Regulation FD disclosure
- 4 Planned sale SVP, CHIEF HR OFFICER sold 1,622 shares at $82.40 ($133,653)
- 4 Planned sale SR. VP, GENERAL COUNSEL & SEC. sold 400 shares at $82.32 ($32,928)
- 4 Open-market sale Director sold 1,800 shares at $81.15 ($146,070)
- 144 Insider Sale of Securities
- 8-K Event Executive or director change · Regulation FD disclosure
- 4 Open-market sale Director sold 8,643 shares at $86.88 ($750,904)
- 4 Open-market sale SVP - CORP. DEV. & STRATEGY sold 14,736 shares at an average $89.06 ($1,312,435)
- 4 Planned sale SR. VP, GENERAL COUNSEL & SEC. sold 400 shares at $87.27 ($34,908)
- 144 Insider Sale of Securities
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 8-K Event Results of operations · Regulation FD disclosure
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
Page 6 of 90 · 1,784 filings